Print this page Close this page

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1446177

Palatin Technologies, Inc. - Product Pipeline Review - Q4 2010

Description:
Palatin Technologies, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Ore Pharmaceuticals IncPalatin Technologies, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Ore Pharmaceuticals IncPalatin Technologies, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ore Pharmaceuticals IncPalatin Technologies, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ore Pharmaceuticals IncPalatin Technologies, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ore Pharmaceuticals IncPalatin Technologies, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Ore Pharmaceuticals IncPalatin Technologies, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ore Pharmaceuticals IncPalatin Technologies, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ore Pharmaceuticals IncPalatin Technologies, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ore Pharmaceuticals IncPalatin Technologies, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ore Pharmaceuticals IncPalatin Technologies, Inc. and identify potential opportunities in those areas.
Contents:

List of Tables
List of Figures
Palatin Technologies, Inc. Snapshot
Palatin Technologies, Inc. Overview
Key Information
Key Facts
Palatin Technologies, Inc. – Research and Development Overview
Key Therapeutic Areas
Palatin Technologies, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Palatin Technologies, Inc. – Pipeline Products Glance
Palatin Technologies, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Palatin Technologies, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Palatin Technologies, Inc. – Drug Profiles
Bremelanotide
Product Description
Mechanism of Action
R&D Progress
PL-3994
Product Description
Mechanism of Action
R&D Progress
MC4-R compound
Product Description
Mechanism of Action
R&D Progress
PL-3994
Product Description
Mechanism of Action
R&D Progress
PL-6983
Product Description
Mechanism of Action
R&D Progress
Palatin Technologies, Inc. – Pipeline Analysis
Palatin Technologies, Inc. – Pipeline Products by Therapeutic Class
Palatin Technologies, Inc. Pipeline Products By Target
Palatin Technologies, Inc. – Pipeline Products by Route of Administration
Palatin Technologies, Inc. – Pipeline Products by Molecule Type
Palatin Technologies, Inc. – Recent Pipeline Updates
Palatin Technologies, Inc. – Company Statement
Palatin Technologies, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 02, 2010: Palatin Technologies Completes First Cohort Dosing Study Of Bremelanotide For The Treatment Of Sexual Dysfunction
Aug 17, 2010: Palatin Announces Positive Safety Results From Phase I Subcutaneous Bremelanotide Trial In Men
Jun 21, 2010: Palatin Technologies Announces Positive Preclinical Data With PL-3994 For Asthma Indications
Dec 08, 2009: Palatin Technologies, Inc. Reports Positive Bremelanotide Study, Improved Safety Profile With Subcutaneous Administration
Dec 08, 2009: Palatin Technologies, Inc. Reports Positive Bremelanotide Study, Improved Safety Profile With Subcutaneous Administration
Sep 15, 2009: Palatin Technologies, Inc. Announces Pl-3994 Poster Presentation At 2009 Heart Failure Society Of America Annual Meeting
Aug 06, 2009: Palatin Technologies, Inc. Receives U.S. Patent Allowance For Heart Failure Drug Candidate
Sep 24, 2008: Palatin Technologies Presents PL-3994 Clinical Trial Results At The 12th Annual Scientific Meeting Of The Heart Failure Association Of America
Aug 14, 2008: Palatin Technologies, Inc. Reports Positive Results Of Phase 2A Clinical Study With Pl-3994 For The Treatment Of Heart Failure
May 20, 2008: Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With Pl-3994
Financial Deals Landscape
Palatin Technologies, Inc., Deals Volume Summary, 2004 to YTD 2010
Palatin Technologies, Inc., Deals Summary By Region, 2004 to YTD 2010
Palatin Technologies, Inc., Deals Summary, 2004 to YTD 2010
Palatin Technologies, Inc. Detailed Deal Summary
Equity Offering
Palatin Technologies Completes Registered Direct Offering Of $3 Million
Palatin Technologies Completes Private Placement Of $27.5 Million
Palatin Technologies Completes Private Placement Of $27 Million
Palatin Technologies Completes Private Placement Of $23 Million
Praj Industries Sgns Joint Venture Agreement with Tata Chemicals
Mallinckrodt Expands Co-Marketing Agreement Wtih Palatin Technologies
King Pharmaceuticals Signs Co-Development Agreement With Palatin Technologies
Palatin Technologies Terminates Agreement With King Pharmaceuticals
Licensing Agreements
Palatin Techologies Extends License Agreement With Astrazeneca
Palatin Technologies Amends Licensing Agreement With Astrazeneca
Nuvo Research Enters Into Licensing Agreement Palatin Technologies
AstraZeneca Enters Into Licensing Agreement With Palatin Technologies
Competitive Technologies Terminates Licensing Agreement With Palatin Technologies
King Pharmaceuticals Terminates Licensing Agreement With Palatin Technologies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed Saturday, May 25, 2013
5:53:30 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Palatin Technologies, Inc. - Product Pipeline Review - Q4 2010

Web Address

http://www.researchandmarkets.com/reports/1446177

Office Code

OC8DIQSMQVRSWQ

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User EURO€ 384.00
Electronic (PDF) - Site License EURO€ 769.00
Electronic (PDF) - Enterprisewide EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Saturday, May 25, 2013
5:53:30 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)